Semrau S - Search Results

1

Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy.

Guckenberger M, Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Ganswindt U, Hass P, Henkenberens C, Holy R, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Semrau S, Streblow J, Wendt TG, Wittig A, Flentje M, Sterzing F. Guckenberger M, et al. Among authors: semrau s. Radiother Oncol. 2016 Mar;118(3):485-91. doi: 10.1016/j.radonc.2015.09.008. Epub 2015 Sep 15. Radiother Oncol. 2016. PMID: 26385265

2

ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity.

Agaimy A, Dermawan JK, Haller F, Semrau S, Meidenbauer N, Stoehr R, Lax S, Hartmann A, Zou YS, Xing D, Tögel L, Gross JM, Michal M. Agaimy A, et al. Among authors: semrau s. Virchows Arch. 2024 Nov;485(5):805-813. doi: 10.1007/s00428-024-03908-3. Epub 2024 Aug 28. Virchows Arch. 2024. PMID: 39196362 Free PMC article.

3

Comprehensive multimodal deep learning survival prediction enabled by a transformer architecture: A multicenter study in glioblastoma.

Gomaa A, Huang Y, Hagag A, Schmitter C, Höfler D, Weissmann T, Breininger K, Schmidt M, Stritzelberger J, Delev D, Coras R, Dörfler A, Schnell O, Frey B, Gaipl US, Semrau S, Bert C, Hau P, Fietkau R, Putz F. Gomaa A, et al. Among authors: semrau s. Neurooncol Adv. 2024 Jul 11;6(1):vdae122. doi: 10.1093/noajnl/vdae122. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 39156618 Free PMC article.

4

[Through the labyrinth towards the goal: doxorubicin/trabectedin in metastatic and initially unresectable leiomyosarcoma].

Grabenbauer F, Semrau S. Grabenbauer F, et al. Among authors: semrau s. Strahlenther Onkol. 2024 Nov 28. doi: 10.1007/s00066-024-02324-5. Online ahead of print. Strahlenther Onkol. 2024. PMID: 39609268 German. No abstract available.

5

Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.

Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Fietkau R. Semrau S, et al. Strahlenther Onkol. 2003 Dec;179(12):823-31. doi: 10.1007/s00066-003-1127-8. Strahlenther Onkol. 2003. PMID: 14652671

6

Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study.

Beckmann G, Fietkau R, Huber RM, Kleine P, Schmidt M, Semrau S, Aubert D, Fittipaldo A, Flentje M. Beckmann G, et al. Among authors: semrau s. Onkologie. 2006 Apr;29(4):137-42. doi: 10.1159/000092062. Epub 2006 Mar 22. Onkologie. 2006. PMID: 16601369 Free article. Clinical Trial.

7

6-year experience of concurrent radiochemotherapy with vinorelbine plus a platinum compound in multimorbid or aged patients with inoperable non-small cell lung cancer.

Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Klautke G, Fietkau R. Semrau S, et al. Strahlenther Onkol. 2007 Jan;183(1):30-5. doi: 10.1007/s00066-007-1593-5. Strahlenther Onkol. 2007. PMID: 17225943 Clinical Trial.

8

Baseline cardiopulmonary function as an independent prognostic factor for survival of inoperable non-small-cell lung cancer after concurrent chemoradiotherapy: a single-center analysis of 161 cases.

Semrau S, Klautke G, Fietkau R. Semrau S, et al. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):96-104. doi: 10.1016/j.ijrobp.2009.10.010. Epub 2010 Mar 28. Int J Radiat Oncol Biol Phys. 2011. PMID: 20350789

9

Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis.

Guckenberger M, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N. Guckenberger M, et al. Among authors: semrau s. J Thorac Oncol. 2013 Aug;8(8):1050-8. doi: 10.1097/JTO.0b013e318293dc45. J Thorac Oncol. 2013. PMID: 23817193 Free article.

10

Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.

Guckenberger M, Klement RJ, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N, Flentje M. Guckenberger M, et al. Among authors: semrau s. Radiother Oncol. 2013 Oct;109(1):13-20. doi: 10.1016/j.radonc.2013.09.005. Epub 2013 Oct 30. Radiother Oncol. 2013. PMID: 24183066

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters